Advertisement
ABBV vs BIIB
Which Stock Would AI Choose? AbbVie (ABBV) vs. Biogen (BIIB) Stock Comparison
Key Takeaways
- AbbVie (ABBV) is a diversified large-cap biopharmaceutical with roughly $67 billion in expected 2026 revenue, while Biogen (BIIB) is a smaller, neurology-focused biotech generating closer to $10 billion annually.
- AbbVie is absorbing the patent-driven decline of Humira through fast-growing immunology drugs Skyrizi and Rinvoq; Biogen is managing multiple sclerosis erosion while pivoting toward Alzheimer's, rare disease, and immunology pipelines.
- Both stocks have risen sharply in recent months, but Biogen's momentum (roughly 28%–30% year-to-date) has outpaced AbbVie's steadier gains.
- AbbVie offers a dividend and lower volatility, while Biogen carries higher beta and more binary clinical-catalyst risk.
- Analyst consensus is "Buy" on both names, with valuation multiples reflecting differing growth and risk profiles.
Introduction
Investors weighing large-cap stability against mid-cap turnaround potential often find themselves comparing ABBV and BIIB. AbbVie is a diversified biopharmaceutical giant built on immunology, neuroscience, oncology, and aesthetics; Biogen is a focused neurology and rare-disease specialist rebuilding its growth story around Alzheimer's and immunology. This stock comparison is relevant to income-oriented investors, growth-focused traders, and anyone assessing relative performance and market positioning across two very different healthcare business models. Both names have generated notable gains in recent months, yet the drivers of those gains differ meaningfully.
ABBV Overview and Recent Performance
ABBV (AbbVie Inc.) is a research-based biopharmaceutical company spanning immunology, oncology, neuroscience, and aesthetics. The company has navigated the loss of exclusivity on its former blockbuster Humira by shifting growth to newer immunology therapies Skyrizi and Rinvoq, which together have been growing at roughly 20% or more year over year and are expected to exceed $31 billion in combined 2026 sales. Neuroscience products such as Vraylar, Ubrelvy, Qulipta, and the newer Parkinson's treatment Vyalev have added a second growth leg.
In recent market activity, the stock has traded near multi-year highs, with a roughly 7%–9% gain over the trailing month and a 20%–22% year-to-date advance. Recent weeks brought a steady stream of pipeline news, including two FDA (Food and Drug Administration) Breakthrough Therapy Designations for the investigational cancer drug telisotuzumab adizutecan, positive Phase 3 data for epcoritamab in lymphoma, and the closing of the Apogee Therapeutics acquisition. AbbVie also pays a dividend yielding around 2.5%, and its low beta reflects its comparatively defensive, diversified profile.
BIIB Overview and Recent Performance
BIIB (Biogen Inc.) is a biotechnology company focused on neurology, rare disease, and immunology. Its legacy multiple sclerosis (MS) franchise has been declining under generic and biosimilar competition, but newer products—including Leqembi for Alzheimer's disease (developed with Eisai), Skyclarys, Qalsody, and Zurzuvae—are offsetting some of that erosion. Biogen has also strengthened its pipeline through acquisitions, including Apellis Pharmaceuticals and RayThera.
Biogen's shares have climbed roughly 28%–30% year to date and set a 52-week high in recent trading, supported by upbeat clinical data and an analyst upgrade to Overweight with a Street-high price target. The market has focused on late-stage catalysts, particularly felzartamab in antibody-mediated rejection of kidney transplants and litifilimab in lupus. However, full-year 2026 revenue is still expected to decline by a mid-single-digit percentage, and the company's earnings guidance reflects acquisition-related charges, underscoring that the turnaround remains a work in progress.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's AI trading bots. Tickeron maintains hundreds of AI trading bots capable of trading thousands of different tickers, but only the strategies deemed most suitable for current market conditions earn a place in this section. These bots vary widely in trading style, strategy, timeframe, performance, and the set of tickers they trade—ranging from short-interval day trading to longer-horizon swing and trend approaches, each with its own win-rate and risk metrics. Browsing the Trending AI Robots list can help traders see which automated strategies are currently resonating with market conditions.
Head-to-Head Comparison
The most fundamental contrast is scale and diversification. AbbVie's business spans multiple therapeutic areas and includes an aesthetics franchise, providing broad revenue resilience and a dividend; Biogen is far more concentrated, with outsized dependence on a smaller number of neurology and pipeline assets. This difference shows up in risk: AbbVie's beta is notably lower than Biogen's, reflecting more stable price behavior, whereas Biogen's shares can move sharply on single clinical readouts.
Growth drivers also diverge. AbbVie's growth is already visible in commercial products, with Skyrizi and Rinvoq delivering double-digit gains. Biogen's growth is more prospective, hinging on future data releases for felzartamab and litifilimab and on broader Leqembi adoption. Consequently, Biogen carries higher catalyst risk but arguably larger potential upside per successful outcome.
On market sentiment, both stocks carry "Buy" consensus ratings. AbbVie trades at a trailing price-to-earnings (P/E) ratio that appears elevated but a forward multiple broadly in line with peers; Biogen trades at a lower forward multiple that reflects earnings uncertainty from restructuring and acquisition costs. For income-focused investors, AbbVie's dividend is a clear differentiator, while Biogen's momentum and catalyst path appeal more to growth-oriented traders.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely tilt toward ABBV for trend consistency and stability. AbbVie combines demonstrated commercial momentum, a diversified revenue base, lower volatility, and a steady cadence of positive pipeline and regulatory developments—attributes that tend to score well on trend-consistency and stability metrics. Biogen offers stronger recent price momentum and potentially larger catalyst-driven upside, but its higher volatility and reliance on binary clinical outcomes introduce greater variability. Probabilistically, the AI would favor AbbVie's more consistent risk-reward profile in the current environment while acknowledging Biogen as a higher-beta alternative for those seeking catalyst exposure.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a Buy and BIIB is a StrongBuy.
ABBV's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ABBV turned positive on October 07, 2026. Looking at past instances where ABBV's MACD turned positive, the stock continued to rise in 34 of 46 cases over the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on ABBV as a result. In 52 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
Following a +1.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 220 of 361 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 224 of 356 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.
Bearish Trend Analysis
The 10-day RSI Indicator for ABBV moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator moved out of overbought territory. In 19 of the 46 cases, the stock moved lower in the following days. This puts the odds of a move lower at 41%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.
ABBV broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (-84.914) is very low in comparison to the industry average of (-3.019). ABBV has a moderately high P/E Ratio (80.562) as compared to the industry average of (21.251). Projected Growth (PEG Ratio) (0.544) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.041) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 12 (best 1 - 100 worst), indicating outstanding price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
BIIB's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for BIIB turned positive on October 13, 2026. Looking at past instances where BIIB's MACD turned positive, the stock continued to rise in 39 of 60 cases over the following month. The odds of a continued upward trend are 65%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on BIIB as a result. In 50 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
Following a +4.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in 166 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
The Aroon Indicator entered an Uptrend today. In 122 of 197 cases where BIIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
BIIB broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 6 (best 1 - 100 worst), indicating outstanding price growth. BIIB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.990) is normal, around the industry mean (-3.019). P/E Ratio (44.690) is within average values for comparable stocks, (21.251). Projected Growth (PEG Ratio) (2.357) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (3.189) is also within normal values, averaging (4.033).
The Tickeron SMR rating for this company is 84 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
ABBV | BIIB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 43 | 25 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | 80 Overvalued | |
PROFIT vs RISK RATING 1..100 | 3 | 100 | |
SMR RATING 1..100 | 1 | 84 | |
PRICE GROWTH RATING 1..100 | 12 | 6 | |
P/E GROWTH RATING 1..100 | 74 | 3 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABBV's Valuation (3) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (80) in the Biotechnology industry. This means that ABBV’s stock grew significantly faster than BIIB’s over the last 12 months.
ABBV's Profit vs Risk Rating (3) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (100) in the Biotechnology industry. This means that ABBV’s stock grew significantly faster than BIIB’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (84) in the Biotechnology industry. This means that ABBV’s stock grew significantly faster than BIIB’s over the last 12 months.
BIIB's Price Growth Rating (6) in the Biotechnology industry is in the same range as ABBV (12) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to ABBV’s over the last 12 months.
BIIB's P/E Growth Rating (3) in the Biotechnology industry is significantly better than the same rating for ABBV (74) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew significantly faster than ABBV’s over the last 12 months.
| ABBV | BIIB | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 41% | 1 day ago 75% |
| Stochastic ODDS (%) | 1 day ago 40% | 1 day ago 71% |
| Momentum ODDS (%) | 1 day ago 68% | 1 day ago 59% |
| MACD ODDS (%) | 1 day ago 74% | 1 day ago 65% |
| TrendWeek ODDS (%) | 1 day ago 63% | 1 day ago 61% |
| TrendMonth ODDS (%) | 1 day ago 64% | 1 day ago 65% |
| Advances ODDS (%) | 8 days ago 61% | 4 days ago 59% |
| Declines ODDS (%) | 23 days ago 46% | 16 days ago 68% |
| BollingerBands ODDS (%) | 1 day ago 40% | 1 day ago 70% |
| Aroon ODDS (%) | 1 day ago 63% | 1 day ago 62% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 4 FA rating(s) are green while BIIB’s FA Score has 2 green FA rating(s).
- ABBV’s FA Score: 4 green, 1 red.
- BIIB’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 4 TA indicator(s) are bullish while BIIB’s TA Score has 4 bullish TA indicator(s).
- ABBV’s TA Score: 4 bullish, 4 bearish.
- BIIB’s TA Score: 4 bullish, 4 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +0.63% price change this week, while BIIB (@Pharmaceuticals: Major) price change was +7.86% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.32%. For the same industry, the average monthly price growth was -5.34%, and the average quarterly price growth was +5.08%.
Reported Earning Dates
ABBV is expected to report earnings on Oct 30, 2026.
BIIB is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+0.32% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
BIIB and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AZN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AZN could also see price increases.
| Ticker / NAME | Correlation To BIIB | 1D Price Change % | ||
|---|---|---|---|---|
| BIIB | 100% | +5.34% | ||
| AZN - BIIB | 49% Loosely correlated | +2.45% | ||
| AMGN - BIIB | 48% Loosely correlated | +2.04% | ||
| PFE - BIIB | 48% Loosely correlated | +1.91% | ||
| MRK - BIIB | 46% Loosely correlated | -1.76% | ||
| ABBV - BIIB | 41% Loosely correlated | +0.14% | ||
More | ||||